Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | The benefits of GvHD risk stratification

Ernst Holler • 21 Mar 2022
EBMT 2022
General

Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany comments on the benefits of risk stratification for graft-versus-host disease (GvHD). Currently, risk stratification is based either on clinical risk or on the identification of specific biomarkers, but in the future, these may merge into a model combining both clinical factors and biomarkers, resulting in a more accurate approach to predict both chronic and acute GvHD. GvHD is typically managed with glucocorticoids, which are known to have important side effects. Prof. Holler explains that risk stratification models may help determine the appropriate dose of glucocorticoids for each individual patient, thereby avoiding unnecessary side effects. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Ernst Holler

2:39
Pathophysiology of GvHD
Ernst Holler • 21 Mar 2022
4:34
Modulation of the microbiota for the treatment of GvHD
Ernst Holler • 21 Mar 2022
1:28
Improving the management of GvHD
Ernst Holler • 21 Mar 2022
7:43
The pros and cons of gut decontamination pre-transplant
Ernst Holler • 11 Oct 2021

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals